ALX Oncology Q4 2023 net loss $45.5M; cash $218.1M; ASPEN-06 interim ORR 52%

ALX ONCOLOGY HOLDINGS INC

GAAP net loss Q4 2023: $45.5M ($0.93/share); FY 2023 net loss $160.8M ($3.74/share).
Cash, equivalents, investments $218.1M at Dec 31, 2023; runway into early 2026.
R&D expenses Q4 2023: $41.8M (up from $25.2M Q4 2022) due to more active trials.
ASPEN-06 interim: ORR 52% evorpacept combo vs 22% control; mDOR not reached vs 7.4 mo.
Anticipated milestones: ASPEN-06 top-line all 122 subjects June-July 2024; Phase 3 start Q4 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ALX ONCOLOGY HOLDINGS INC reported the fourth quarter and full year ended December 31, 2023 results: net income GAAP net loss was $45.5 million for the fourth quarter ended December 31, 2023, or ($0.93) per basic and diluted share, EPS ($0.93) per basic and diluted share.

Period: the fourth quarter and full year ended December 31, 2023
Net income: GAAP net loss was $45.5 million for the fourth quarter ended December 31, 2023, or ($0.93) per basic and diluted share
EPS: ($0.93) per basic and diluted share
Result: reported results

Exact text from the filing

On March 7, 2024, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-027925

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.